REVB (Revelation Biosciences) Short-Term Debt to Capital
The market dynamics of Revelation Biosciences (REVB) reflected in the quotes on GURU.Markets show a debt-to-equity ratio of 0.02. The immune therapy developer integrates ESG principles and bioethics into its scientific research, reducing harmful emissions. The implementation of automated cytokine analysis systems optimizes personnel costs. The expected completion of primary tests for new drugs will serve as a growth driver, despite current R&D expenses.
Analytical breakdowns for Revelation Biosciences
- stock quotes and analyst forecast:
- business market valuation indicators:
- book capitalization information:
- company liabilities and liquidity data:
Total Debt to Capital Revelation Biosciences|REVB - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Revelation Biosciences, Inc.|REVB - Aggregate Debt Obligations|Debts to Book Capitalization Revelation Biosciences Inc|REVB - Long-Term Debt Volume|Company Short-Term Debt Revelation Biosciences|Quick Liquidity revbiosciences.com
- company profitability and valuation multiples indicators:
Fundamental valuation:Revelation Bio
For Revelation Biosciences (REVB), which is scaling clinical trials for immunomodulators, the short-term debt-to-equity ratio reflects the current dependence of operational activities on quick loans. This metric correlates liabilities with a maturity of up to one year against total equity, allowing investors to assess liquidity risk and balance sheet resilience to market shocks while awaiting molecular data.
Main competitors
Short-Term Debt to Capital ARGX|BNTX (BioNTech Pharma) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ABVX (Abivax Pharma)|Short-Term Debt to Capital admabiologics.com ADMA|PTGX - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital IMVT (Immunovant Inc)|Kiniksa Pharmaceuticals Ltd (KNSA) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Grifols Biemat|ADPT (Adaptive Biotechnologies) - Short-Term Debt to Capital|Short-Term Debt to Capital celldex.com|Short-Term Debt to Equity Ratio AUPH (Aurinia Pharmaceuticals Inc.)|BCRX (BioCryst Pharmaceuticals, Inc.) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital VERA (Vera Pharma)|Short-Term Debt to Capital Coefficient Dianthus Corp (DNTH)|PHVS - Short-Term Debt to Equity|AbCellera Biologics Inc (ABCL) - Short-Term Debt to Equity Ratio|Tourmaline Bio (TRML) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Precigen Inc|Short-Term Debt to Equity Ratio PHAR|Short-Term Debt to Capital Nektar Corp|Short-Term Debt to Equity Upstream Bio Inc (UPB)|zenasbio.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital IMNM (Immunome)|Gossamer Bio Inc (GOSS) - Current Liabilities to Capital|KALV - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital SEPN (Septerna Pharma)|PVLA: Short-Term Debt to Capital|Current Liabilities to Capital savarapharma.com (SVRA)|Short-Term Debt to Equity Ratio RIGL|Short-Term Debt to Equity ANAB|Short-Term Debt to Capital ATXS|ENGN - Current Liabilities to Capital|Short-Term Debt to Equity RAPT Therapeutics RAPT|Aerovate Therapeutics, Inc. - Short-Term Debt to Equity|Aclaris Therapeutics, Inc. - Short-Term Debt to Capital|KYTX - Short-Term Debt to Capital|TLSA (Tiziana Life Sciences PLC) - Short-Term Debt to Equity Ratio|CABA: Short-Term Loans to Capital Ratio|VTYX (Ventyx Biosciences) - Short-Term Debt to Capital|theratech.com (THTX) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Avalo Therapeutics (AVTX)|ELDN - Current Liabilities to Capital|Short-Term Debt to Equity Agenus Inc AGEN|CLYM: Short-Term Debt to Capital Ratio|ZURA: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital ATYR (atyrpharma.com)|ADAG: Short-Term Debt to Capital|IMA (Ikena Oncology) - Short-Term Debt to Equity|STTK (Shattuck Labs Inc) - Short-Term Debt to Capital|Equillium Bio (EQ) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Connect Biopharma (CNTB)|IMUX - Current Liabilities to Capital|Short-Term Debt to Equity Atara Bio ATRA|Short-Term Debt to Capital Coefficient InflaRx NV (IFRX)|X4 Pharma - Short-Term Debt to Capital|Adicet Bio (ACET) - Short-Term Debt to Equity Ratio|CELU: Short-Term Debt to Capital|INMB - Short-Term Debt to Capital Coefficient|BRNS (Barinthus Biotherapeutics plc) - Short-Term Debt to Capital|Current Liabilities to Capital Kezar Life Sciences Inc. KZR|Short-Term Debt to Equity SAB Biotherapeutics, Inc (SABS)|Akari Therapeutics, Plc - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital ENLV (Enlivex Therapeutics Ltd.)|QTTB - Short-Term Debt to Equity Ratio|GeoVax - Short-Term Debt to Capital|Current Liabilities to Capital Edesa Biotech Inc|iBio Corp (IBIO) - Short-Term Debt to Equity|CARM - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity XTL Biopharmaceuticals|BOLT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital HCWB|APVO - Current Liabilities to Capital|AIM ImmunoTech Inc. - Short-Term Debt to Equity Ratio|Aditxt Inc. - Short-Term Debt to Equity|GRI Bio, Inc. - Short-Term Debt to Capital|XRTX: Short-Term Debt to Equity|Vyome Holdings (HIND) - Short-Term Debt to Equity|Current Liabilities to Equity INDP (Indaptus Therapeutics Inc)|SCNI (Scinai) - Short-Term Debt to Capital|CALI: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital AFMD|Short-Term Debt to Capital allakos.com (ALLK)|Short-Term Debt to Equity HOOKIPA Pharma HOOK|Ratio of Short-Term Indebtedness to Capital IGMS|ITOS - Short-Term Debt to Equity|Ocean Biomedical Corp (OCEA) - Short-Term Debt to Equity Ratio|TCBP: Short-Term Debt to Capital|thirdharmonicbio.com (THRD) - Short-Term Debt to Capital